Press Releases :: ProMIS Neurosciences, Inc. (PMN)

Oct 11, 2018

ProMIS Neurosciences Identifies Novel Antibody Drug Candidates for Parkinson's Disease

Sep 17, 2018

ProMIS Neurosciences to Present at Extraordinary Futures Investment Conference

Sep 13, 2018

ProMIS Neurosciences Appoints James Kupiec, MD as Chief Medical Officer

Aug 29, 2018

ProMIS Neurosciences Issues Narrated Overview of Second Quarter 2018 Results

Aug 22, 2018

ProMIS Neurosciences to Present at 20th Annual Global Investment Conference

Aug 21, 2018

ProMIS Neurosciences Oligomer Selective Antibody Therapeutic for Alzheimer's Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies in Clinical Development

Aug 14, 2018

ProMIS Neurosciences Announces Second Quarter 2018 Results

Aug 7, 2018

ProMIS Neurosciences Issues Narrated Commentary on Key Learnings from AAIC 2018

Jul 31, 2018

ProMIS Neurosciences Issues White Paper Entitled 'State of the Art at AAIC 2018'

Jul 10, 2018

ProMIS Neurosciences to Present Preclinical Data on Alzheimer's Disease Therapeutic Antibody PMN310 at Alzheimer's Association International Conference